Novartis (NYSE:NVS) reported positive Phase 3 REMODEL-1 and REMODEL-2 trial results showing remibrutinib reduced annualized relapse rates compared with teriflunomide in adults with relapsing multiple sclerosis.
Novartis (NYSE:NVS) reported fourth-quarter adjusted earnings that beat analyst estimates on Wednesday, but the Swiss pharmaceutical giant issued a cautious 2026 outlook as it prepares to navigate the largest wave of patent expirations in its history.
Novartis (NYSE:NVS) reported Q2 2026 net sales of $14.41 billion, up 3% in dollars and 1% at constant currencies.
Novartis (NYSE:NVS) has agreed to acquire Myricx Bio, a U.K.-based biotechnology company, in a transaction valued at up to $1.5 billion.
